- Home
- APM vs KLTO Comparison
APM vs KLTO Comparison
Compare APM & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- KLTO
- Stock Information
- Founded
- APM 2010
- KLTO 2019
- Country
- APM United Kingdom
- KLTO United States
- Employees
- APM N/A
- KLTO N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- KLTO
- Sector
- APM Health Care
- KLTO
- Exchange
- APM Nasdaq
- KLTO NYSE
- Market Cap
- APM 6.1M
- KLTO 7.1M
- IPO Year
- APM 2018
- KLTO N/A
- Fundamental
- Price
- APM $1.07
- KLTO $0.21
- Analyst Decision
- APM
- KLTO
- Analyst Count
- APM 0
- KLTO 0
- Target Price
- APM N/A
- KLTO N/A
- AVG Volume (30 Days)
- APM 81.2K
- KLTO 35.4M
- Earning Date
- APM 06-17-2025
- KLTO 05-15-2025
- Dividend Yield
- APM N/A
- KLTO N/A
- EPS Growth
- APM N/A
- KLTO N/A
- EPS
- APM N/A
- KLTO N/A
- Revenue
- APM N/A
- KLTO N/A
- Revenue This Year
- APM N/A
- KLTO N/A
- Revenue Next Year
- APM N/A
- KLTO N/A
- P/E Ratio
- APM N/A
- KLTO N/A
- Revenue Growth
- APM N/A
- KLTO N/A
- 52 Week Low
- APM $0.46
- KLTO $0.11
- 52 Week High
- APM $7.49
- KLTO $0.99
- Technical
- Relative Strength Index (RSI)
- APM 58.89
- KLTO N/A
- Support Level
- APM $0.83
- KLTO N/A
- Resistance Level
- APM $1.35
- KLTO N/A
- Average True Range (ATR)
- APM 0.12
- KLTO 0.00
- MACD
- APM 0.02
- KLTO 0.00
- Stochastic Oscillator
- APM 46.97
- KLTO 0.00
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.